Understanding characteristics of patients with recessive dystrophic epidermolysis bullosa

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with recessive dystrophic epidermolysis bullosa (RDEB), a genetic skin disorder characterized by painful blisters and wounds. Participants will undergo a thorough medical history review, skin examinations, and may have photographs taken of their condition. Blood tests will be conducted to assess overall health, including screenings for Hepatitis B, Hepatitis C, and HIV, along with potential genetic testing. The study aims to gather data that could help identify candidates for future treatment studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical diagnosis of RDEB by local dermatologist
* 7 years of age or older

Exclusion Criteria:

-Medical instability limiting ability to travel to Stanford University Medical Center

Where it's running

• Stanford University School of Medicine
  Stanford, California, United States Recruiting

Study contacts

• Principal investigator: Jean Tang, MD, PhD — Stanford University
• Study coordinator: Irene Bailey-Healy
• Email: baileyhi@stanford.edu
• Phone: (650) 721-7149

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Observing corneal abrasions in patients with Dystrophic Epidermolysis Bullosa

  This study looks at how corneal abrasions develop over time in people with Dystrophic Epidermolysis Bullosa by tracking their symptoms through weekly diaries and monthly questionnaires.

  Recruiting Krystal Biotech, Inc. · Pittsburgh, Pennsylvania · NCT06563414

• Gene-modified autologous skin graft (GMEB-SASS) for RDEB

  This trial will try a gene-modified skin graft grown from a patient's own cells to help wounds heal in people with recessive dystrophic epidermolysis bullosa (RDEB).

  Recruiting Phase 1/2 CHU de Quebec-Universite Laval · Toronto, Ontario · NCT07193134

• Energy-F703EB Cream for Epidermolysis Bullosa: a skin cream test in adults

  This phase 2 study tests ENERGI-F703EB Cream versus a matching vehicle to see if it is safe and helps small EB skin lesions in adults.

  Recruiting Phase 2 Energenesis Biomedical Co., Ltd. · Tainan · NCT07858422

• Ev.FV to heal wounds in dystrophic epidermolysis bullosa

  This trial will test whether Ev.FV, a mesenchymal stem cell-derived extracellular vesicle therapy, helps heal wounds in people with dystrophic epidermolysis bullosa.

  Recruiting Phase 1/2 Isfahan University of Medical Sciences · Isfahan · NCT07230223

• KB803 eye drops versus placebo for people with dystrophic epidermolysis bullosa

  This trial tests whether KB803 eye drops, given three times a week, can reduce recurrent corneal abrasions in children and adults with dystrophic epidermolysis bullosa.

  Recruiting at 5 sites Phase 3 Krystal Biotech, Inc. · Rancho Santa Margarita, California and 4 other locations · NCT07016750

• Using IV immunoglobulin to lower collagen VII antibodies in dystrophic epidermolysis bullosa

  This trial tests whether IV immunoglobulin given to people with recessive dystrophic epidermolysis bullosa who are on VYJUVEK helps wounds heal faster and lowers collagen VII and HSV‑1 antibody levels.

  Recruiting Phase 1/2 Stanford University · Redwood City, California · NCT06834035

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.